Stoppa Am
Impact in
- Hematology top 5%
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
-
- Neutropenia and Cancer Infections
- Cancer Treatment and Pharmacology
Papers in
- Hematology 15
- Hematopoietic Stem Cell Transplantation 9
- Acute Myeloid Leukemia Research 3
- Multiple Myeloma Research and Treatments 3
- Chronic Myeloid Leukemia Treatments 2
- Oncology 14
- Neutropenia and Cancer Infections 7
- Cancer Treatment and Pharmacology 4
- Co-authors
- Didier Blaise (11 shared papers)Dominique Maraninchi (10 shared papers)Patrice J. Viens (8 shared papers)Christian Chabannon (5 shared papers)G Novakovitch (5 shared papers)Catherine Faucher (4 shared papers)Diane Coso (4 shared papers)Gérald Marit (6 shared papers)
- Journals
- Bone Marrow Transplantation (4 papers)Leukemia (1 paper)British Journal of Cancer (1 paper)Leukemia & lymphoma (1 paper)PubMed (14 papers)
- Partner nations
- FranceCanadaUnited States
In The Last Decade
Stoppa Am
21 papers receiving 406 citations
Peers
Comparison fields: 5 of 54
- Hematology 313
- Oncology 145
- Genetics 52
- Transplantation 12
- Immunology 60
Countries citing papers authored by Stoppa Am
This map shows the geographic impact of Stoppa Am's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stoppa Am with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stoppa Am more than expected).
Fields of papers citing papers by Stoppa Am
This network shows the impact of papers produced by Stoppa Am. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stoppa Am. The network helps show where Stoppa Am may publish in the future.
Co-authors
The 25 scholars most cited alongside Stoppa Am, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission. | 1990 | 59 |
| 2 | 2008 | 54 | |
| 3 | Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. | 1995 | 42 |
| 4 | 2011 | 36 | |
| 5 | 2004 | 31 | |
| 6 | 2015 | 28 | |
| 7 | Delayed administration of granulocyte colony-stimulating factor after autologous bone marrow transplantation: effect on granulocyte recovery. | 1994 | 24 |
| 8 | Role of splenectomy in incidence and severity of acute graft-versus-host disease: a multicenter study of 157 patients. | 1991 | 23 |
| 9 | 2003 | 20 | |
| 10 | Treatment of acute myeloid leukemia in elderly patients: the influence of maintenance therapy (BGM 84 protocol). | 1990 | 17 |
| 11 | Phase I study of in vivo lenograstim (rHuG-CSF) for stem cell collection demonstrates improved neutrophil recovery after autologous bone marrow transplantation. | 1994 | 15 |
| 12 | 1992 | 13 | |
| 13 | Pilot study of immunotherapy with interleukin-2 after autologous stem cell transplantation in advanced breast cancers. | 2001 | 12 |
| 14 | Anti LFA1 monoclonal antibody for the prevention of graft rejection after T cell-depleted HLA-matched bone marrow transplantation for leukemia in adults. | 1989 | 10 |
| 15 | 2014 | 9 | |
| 16 | Interleukin-2 induces chemotactic deficiency in patients with onco hematologic malignancies and autologous bone marrow transplantation. | 1992 | 8 |
| 17 | Allogeneic versus autologous bone marrow transplantation versus chemotherapy for treatment of acute myeloid leukemia in first complete remission (BGM 84 and BGMT 87 studies). The BGMT Group. | 1991 | 8 |
| 18 | Does more intensive treatment cure more patients with acute myeloid leukemia? The BGMT Group. | 1991 | 6 |
| 19 | Use of recombinant IL-2 (RU49637) after autologous bone marrow transplantation (BMT) in patients with hematological neoplasias: a phase 1 study. | 1991 | 4 |
| 20 | Pentoxifylline in vitro reverses neutrophil chemotactic deficiency induced by interleukin-2 treatment. | 1992 | 3 |
About Stoppa Am
Stoppa Am is a scholar working on Hematology, Oncology, Immunology, Emergency Medicine and Genetics, having authored 21 papers that have together received 425 indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (9 papers), Neutropenia and Cancer Infections (7 papers), Cancer Treatment and Pharmacology (4 papers), Acute Myeloid Leukemia Research (3 papers), Multiple Myeloma Research and Treatments (3 papers), Blood disorders and treatments (3 papers), Chronic Myeloid Leukemia Treatments (2 papers) and Acute Lymphoblastic Leukemia research (2 papers). The work is most often cited by research in Hematology (313 citations), Oncology (145 citations), Genetics (52 citations), Transplantation (12 citations) and Immunology (60 citations). Stoppa Am has collaborated with scholars based in France, Canada and United States. Frequent co-authors include Didier Blaise, Dominique Maraninchi, Patrice J. Viens, Christian Chabannon, G Novakovitch, Catherine Faucher, Diane Coso, Gérald Marit, Gastaut Ja and Mohamad Mohty. Their work appears in journals such as Bone Marrow Transplantation, Leukemia, British Journal of Cancer, Leukemia & lymphoma and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.